{"groups":[{"description":"Participants received tocilizumab 8 mg/kg intravenously every 4 weeks till the end of the study (up to 7 years, 7 months). In addition, participants may have also received disease-modifying anti-rheumatic drugs, non-steroidal anti-inflammatory drugs, and oral corticosteroids at the discretion of the investigator.","id":"FG000","title":"Tocilizumab"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"304"}],"type":"Adverse Event"},{"reasons":[{"groupId":"FG000","numSubjects":"39"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"129"}],"type":"Insufficient Therapeutic Response"},{"reasons":[{"groupId":"FG000","numSubjects":"4"}],"type":"Protocol Violation"},{"reasons":[{"groupId":"FG000","numSubjects":"151"}],"type":"Refused Treatment"},{"reasons":[{"groupId":"FG000","numSubjects":"46"}],"type":"Failure to Return"},{"reasons":[{"groupId":"FG000","numSubjects":"83"}],"type":"Reason not Specified"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"2067"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"1311"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"756"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}]}